| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_716e9a2606ffd4ba1a2a3917e4a402fd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2019-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bed11063ebcc015024f1614826445ad3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4fa38bc08e4c37b59d635d5ea8ce073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b919f1253ea9d6a2994324333ee363dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c367dcb29e63ded3e5a15b5e2d6376e |
| publicationDate |
2019-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019159731-A1 |
| titleOfInvention |
Agent for preventing or improving chronic lung allograft dysfunction |
| abstract |
A purpose of the present invention is to provide an immunosuppressant that can prolong suppression of rejection after lung transplant. An agent for preventing or improving chronic lung allograft dysfunction having an MEK inhibitor as an active ingredient can prolong suppression of rejection after lung transplant and makes it possible to prevent or improve chronic lung allograft dysfunction (CLAD). The agent for preventing or improving chronic lung allograft dysfunction having an MEK inhibitor as an active ingredient is administered to a lung transplant patient who has undergone treatment for acute immune rejection. |
| priorityDate |
2018-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |